Emergence of Daptomycin-Resistant <i>Staphylococcus aureus</i> during Treatment

Abstract

A 68-year-old man with persistent bacteremia accompanying a large iliopsoas abscess, vertebral osteomyelitis, discitis and central venous port infection caused by methicillin-resistant Staphylococcus aureus (MRSA) was admitted to our hospital. During the course of treatment, the emergence of a daptomycin (DAP)-resistant MRSA strain was confirmed; the minimum inhibitory concentration was 1 to 2 μg/mL for vancomycin and more than 1 μg/mL for DAP. Although the bacterial cell wall was not significantly thickened, an increased positive surface charge and single-nucleotide polymorphism within mprF have been confirmed in DAPresistant strains. Still rare, but clinicians need to be cautious of the emergence of DAP-resistant MRSA during treatment.

Identification and Validation of a Novel Antibacterial Compound MZ-01 against Methicillin-Resistant Staphylococcus aureus

“…Several antibiotics, including linezolid and daptomycin, are approved for the treatment of MRSA and are still part of our first and second lines of therapy; vancomycin, linezolid, and clindamycin are used for the treatment of MRSA pneumonia [ 33 ]. However, there has been a rise in multidrug resistance against these antibiotics, which further limits our therapeutic options [ 34 , 35 , 36 , 37 , 38 , 39 , 40 ]. There are several new antibiotics in the pipeline, but they are mostly limited to existing classes and thus have cross-resistance, which highlights the need for the development of novel antibiotic classes [ 41 , 42 ].…”